Compare · MDT vs MOVE
MDT vs MOVE
Side-by-side comparison of Medtronic plc. (MDT) and Corvex Inc. (MOVE): market cap, price performance, sector, and recent activity on the wire.
Summary
- MDT operates in Health Care, while MOVE operates in Technology - the two are in different parts of the market.
- MDT is the larger of the two at $127.84B, about 998.8x MOVE ($128.0M).
- MDT has been more active in the news (14 items in the past 4 weeks vs 7 for MOVE).
- MDT has more recent analyst coverage (25 ratings vs 1 for MOVE).
- Company
- Medtronic plc.
- Corvex Inc.
- Price
- -
- -
- Market cap
- $127.84B
- $128.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- EDP Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 14
- 7
- Recent ratings
- 25
- 1
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Corvex Inc.
Movano Inc., a technology company, develops a smart wearable and continuous glucose monitoring device. Its device enables individuals and their healthcare partners to measure and manage their health conditions. Movano Inc. was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. The company was incorporated in 2018 and is based in Pleasanton, California.
Latest MDT
- Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference
- Medtronic upgraded by Piper Sandler with a new price target
- Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system
- Medtronic to acquire Contego Medical, expanding access to next-generation carotid therapies
- Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
- SEC Form SCHEDULE 13G filed by Medtronic plc.
- Imperative Care Announces Two New Board of Directors Appointments
- Orchestra BioMed Announces Pricing of Public Offering
- Orchestra BioMed Announces Proposed Public Offering
- President Marinaro Michael was granted 6,547 units of Ordinary Shares, increasing direct ownership by 6% to 113,353 units (SEC Form 4)
Latest MOVE
- New insider Brian Dostie claimed ownership of 104,416 shares (SEC Form 3)
- Corvex Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Corvex Signs $103 Million Take-or-Pay Agreement for NVIDIA Blackwell Capacity; $21 Million of Annual Contract Revenue per Megawatt
- SEC Form 10-Q filed by Corvex Inc.
- Corvex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Corvex Reports Third Quarter 2026 Results
- Corvex to Host Third Quarter 2026 Earnings Call on Thursday, November 12, 2026
- SEC Form 8-K filed by Corvex Inc.
- SEC Form 424B5 filed by Corvex Inc.
- SEC Form EFFECT filed by Corvex Inc.